From Agadez to Zinder: estimating coverage of the MenAfriVac (TM) conjugate vaccine against meningococcal serogroup A in Niger, September 2010-January 2012
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Caini, Saverio | - |
dc.contributor.author | Beck, Nam Seon | - |
dc.contributor.author | Yacouba, Harouna | - |
dc.contributor.author | Maiga, Idrissa | - |
dc.contributor.author | Chaibou, Ibrahim | - |
dc.contributor.author | Hinsa, Ide | - |
dc.contributor.author | Adakal, Aboubacar | - |
dc.contributor.author | Issoufou, Aboubacar | - |
dc.contributor.author | Kim, Sung Hye | - |
dc.contributor.author | Pezzoli, Lorenzo | - |
dc.date.accessioned | 2021-12-28T02:20:45Z | - |
dc.date.available | 2021-12-28T02:20:45Z | - |
dc.date.created | 2021-10-17 | - |
dc.date.issued | 2013-03 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/133921 | - |
dc.description.abstract | MenAfriVac (TM) is a conjugate vaccine against meningitis A specifically designed for Africa. In Niger, the MenAfriVac (TM) vaccination campaign was conducted in people aged 1-29 years in three phases. The third phase was conducted in November/December 2011 targeting more than 7 million people. We estimated vaccination coverage for the third phase; classified the 31 target districts according to vaccination coverage levels; analysed the factors associated with being vaccinated; described the reasons for non-vaccination; and estimated coverage of the MenAfriVac (TM) introduction in Niger by aggregating data from all three phases. We classified the districts by clustered lot quality assurance sampling according to a 75% lower threshold and a 90% upper threshold. We estimated coverage using a minimum cluster-sample of 30 x 10 in each region. Two criteria were used to document vaccination status: presentation of vaccination card only or by card and/or verbal history of vaccination (card + history). We surveyed 2390 persons. After the third phase, estimated coverage was 68.8% (95% CI 64.9-72.8) by card only and 90.9% (95% CI 88.6-93.2) by card + history. Five districts were accepted for coverage above 75% based on card only, whereas 25 were accepted based on card + history. Factors positively associated with being vaccinated were younger age (<15 years), female sex, residing in the same household for more than three months, and being informed about the vaccination campaign. The main reason for non-vaccination was not being at home during the campaign. Overall coverage for MenAfriVac (TM) introduction via 3 phases was 76.1% (95% CI: 72.5-79.6) by card only and 91.9% (95%CI: 89.7-94.1) by card + history.Although estimated coverage was high, pockets of non-vaccination probably still exist in the country; thus, the implementation of mop-up campaigns should be considered. Priorities for the future should include incorporating meningitis A vaccination into the existing immunization schedule and assessing its impact at a population level. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Elsevier BV | - |
dc.title | From Agadez to Zinder: estimating coverage of the MenAfriVac (TM) conjugate vaccine against meningococcal serogroup A in Niger, September 2010-January 2012 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Sung Hye | - |
dc.identifier.doi | 10.1016/j.vaccine.2013.01.015 | - |
dc.identifier.scopusid | 2-s2.0-84875256975 | - |
dc.identifier.wosid | 000316535600009 | - |
dc.identifier.bibliographicCitation | Vaccine, v.31, no.12, pp.1597 - 1603 | - |
dc.relation.isPartOf | Vaccine | - |
dc.citation.title | Vaccine | - |
dc.citation.volume | 31 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1597 | - |
dc.citation.endPage | 1603 | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | EPIDEMIC MENINGITIS | - |
dc.subject.keywordPlus | IMMUNIZATION | - |
dc.subject.keywordPlus | CARRIAGE | - |
dc.subject.keywordPlus | CHILDREN | - |
dc.subject.keywordPlus | MEASLES | - |
dc.subject.keywordPlus | CLIMATE | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | PREDICTORS | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordAuthor | Cluster sampling | - |
dc.subject.keywordAuthor | Lot quality assurance sampling | - |
dc.subject.keywordAuthor | MenAfriVac™ | - |
dc.subject.keywordAuthor | Meningococcal meningitis serogroup A | - |
dc.subject.keywordAuthor | Survey | - |
dc.subject.keywordAuthor | Vaccination coverage | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.